AI pathology firm Proscia nets $37M investment

Proscia, a company that uses artificial intelligence to treat and research cancer, has raised $37 million in series C funding.

Advertisement

Founded in 2014, the data-driven software developer uses digital images rather than microscopes to advance precision medicine and pathology in the oncology field. The company said the funding will help scale its commercial operations, grow its distribution partnerships and expand its sales, marketing and support teams.

“Pathology is a multibillion dollar market transitioning to digital,” said Steve Holloway, executive director at market intelligence company Signify Research, in a June 14 Proscia news release. “Adoption has moved beyond the largest life sciences organizations and medical centers as the benefits have become increasingly clear, much like we saw when the digitization of radiology crossed an inflection point.”

The investment round included Highline Capital Management, Triangle Peak Partners and Alpha Intelligence Capital and brought Proscia’s total funding to $72 million. The firm said its users include 10 of the top 20 pharma companies, as well as the federal Joint Pathology Center.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The hidden cost of lost clinical time and how leading health systems are responding

Friday, August 7
12:00 PM - 1:00 PM CDT

Presenters: Kassaundra McKnight-Young, Zebra TechnologiesGregory Carras, Zebra TechnologiesJennifer Gene, Levata

Advertisement

Next Up in Innovation

Advertisement

Comments are closed.